Track topics on Twitter Track topics that are important to you
Cambridge, UK, 6th March, 2017: Cambridge Epigenetix, a pioneer in the development and application of epigenetic technologies, today announces the formation of its Scientific Advisory Board (SAB). The SAB comprises experts for Cambridge Epigenetix’s key focus areas, including oncology, liquid biopsy and ageing. They form a key strategic resource and provide their unique research perspectives as the company transitions towards becoming an integrated commercial epigenetic biomarker discovery venture. The members of the SAB are:
Sir Shankar Balasubramanian FRS, the company’s co-founder, and inventor of our initial proprietary ‘TruMethyl’ technology, will chair the SAB. Professor Sir Balasubramanian is the Herchel Smith Professor of Medicinal Chemistry at the University of Cambridge. He is recognised for his research contributions to the chemical biology of nucleic acids and the genome. He was a founder of Solexa Ltd, and co-inventor of the basic technology underpinning Solexa sequencing, which is the basis of Illumina’s dominant next-generation DNA sequencing business. His research group is based at both the Department of Chemistry and the Cancer Research UK Cambridge Research Institute. His recent awards include the Royal Society Mullard Award (2009), The BBSRC Innovator of the year (2010) and the Tetrahedron Prize (2013). He is a Fellow of The Royal Society, The Academy of Medical Sciences and a member of EMBO.
Wolf Reik, FRS FMedSci, who has been a scientific advisor since the company’s founding in 2012, is Head of the Epigenetics Programme at the Babraham Institute in Cambridge and its Associate Director. He is honorary Professor of Epigenetics at the University of Cambridge and Associate Faculty at the Wellcome Trust Sanger Institute, where he is a founding member of the recently established Centre for Single Cell Genomics. He is a Member of EMBO, Fellow of the Academy of Medical Sciences, Fellow of the Royal Society, and a Member of the Academia Europaea. His research interests are in epigenetics, particularly in epigenetic reprogramming during mammalian development and its role in stem cell biology and inheritance. His current work addresses the mechanisms of genome-wide demethylation in the mammalian germ line, links between reprogramming and pluripotency, the potential for transgenerational epigenetic inheritance, and the role of epigenetic mechanisms in experimental reprogramming. His lab also develops new epigenomics technologies especially in single cells.
Anjana Rao, Ph.D., is Professor and Head of the Division of Signalling and Gene Expression at the La Jolla Institute and the Sanford Consortium for Regenerative Medicine in San Diego. She moved her laboratory from Harvard Medical School to San Diego in 2011. Professor Rao’s team was the first to identify the role of the ten-eleven translocation (TET) family of proteins in epigenetic regulation through the conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC). The characterisation of 5hmC and its utility as a biomarker for a range of important diseases is a cornerstone of Cambridge Epigenetix’s activities. Professor Rao has worked on signaling and gene transcription for many years, is a member of numerous advisory panels, and has received several major awards. She is an elected member of the US National Academy of Sciences, the American Academy of Arts and Sciences and the American Association for the Advancement of Science.
Jay Shendure M.D., Ph.D. is Professor of Genome Sciences at the University of Washington, where his lab's focus is to develop and apply new technologies in genomics and molecular biology, with an emphasis on next-generation DNA sequencing and its applications in human genetics. In addition to pioneering the application of liquid biopsies to identify the contributions of cancerous cells and foetal anomalies, Professor Shendure’s team at the University of Washington reported the first haplotype-resolved genome and epigenome of a human cancer. He is the recipient of the Curt Stern Award from the American Society of Human Genetics in 2012, the FederaPrijs from the Federation of Dutch Medical Scientific Societies in 2013, and a National Institutes of Health Director's Pioneer Award in 2013.
Dr Jason Mellad, CEO at Cambridge Epigenetix, commented: “We are pleased to announce the appointment of the new scientific advisory board. Cambridge Epigenetix is committed to making a significant impact in healthcare, and we are delighted to have secured such eminent SAB members. Their expertise will further help us in supporting our customers to unlock the tremendous potential of epigenetic analysis and biomarker discovery.”
About Cambridge Epigenetix
Cambridge Epigenetix’s mission is to improve health through the routine measurement of the epigenome. Cambridge Epigenetix utilizes innovative technologies, often based on fundamental chemistry, to detect the epigenetic biomarkers that will be most useful in clinical settings. Spun-out of the University of Cambridge in 2012, the Company was founded by Professor Sir Shankar Balasubramanian (co-inventor of Solexa sequencing) and Dr Bobby Yerramilli-Rao to commercialise its founding technology, oxidative bisulfite sequencing (oxBS-Seq), which enables users to quantify, and discriminate between, functionally-distinct DNA modifications – impossible with traditional bisulfite methods. Cambridge Epigenetix is a privately held company headquartered in Cambridge, UK, supported by several high-profile investors: GV (Google Ventures), Sequoia, Syncona, New Science Ventures and the University of Cambridge. The Company is seeking partnerships across a broad range of applications in life sciences, as well as developing its own pipeline. For more information, visit www.cambridge-epigenetix.com
The development and maintenance of an organism is orchestrated by a set of chemical reactions that switch parts of the genome off and on at strategic times and locations. Epigenetics is the study of these reactions and the factors that influence them. ...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...